TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. Angiogenesis is the development of new blood vessels, delivering oxygen and nutrients to the tumor. Anti-angiogenic therapies aim at inhibiting this process, therefore denying the tumor its blood supply and prohibiting its further growth. Angiogenesis is a multi-stage process involving a number of stimulating and inhibiting factors that control the developmental process of endothelial cells. The signaling factors for endothelial cell growth and tumor growth are closely linked and reciprocal . Suppressing angiogenesis and concurrently suppressing tumor growth by inhibiting various stimulating factors or interfering with the angiogenic process is a promising approach in cancer therapy research. Furthermore, anti-angiogenic therapy may reduce the risk associated with the development of drug-resistance to conventional chemotherapy, and permit long-term maintenance of a stable disease status. In addition, using drugs that do not cause limiting side effects will improve both patient's compliance and well-being. Administration of cytotoxic drugs at frequent intervals using significantly lower doses than conventional chemotherapy (metronomic dosing), specifically targets the endothelial compartment of the tumor bed, and has been shown to promote an anti-angiogenic effect . Angiogenesis is susceptible to inhibition by diverse agents, as it is a multi-faceted process with several mechanisms operating in concert to produce new blood vessels. Consequently, combining several agents may result in a synergistic effect that will allow use of lower doses of each component, thus improving the therapy's safety profile whilst maintaining its efficacy.